Who We Are

The Expert of Cellular Resolution Optical Imaging
Generating Superior Images Like No Other Technologies

Founded in 2015, Apollo Medical Optics (AMO) is a medical technology company developing medical imaging system based on the revolutionary technology, Optical Coherence Tomography (OCT).

AMO’s core technology was developed at National Taiwan University (NTU), when AMO’s researchers first began investigating medical optics. Our unique crystal fiber technology brings the OCT to a new era, which gives AMO’s product a competitive advantage, with cellular level resolution and a faster scanning speed.

Our Vision

Redefine what’s possible in medical optical imaging

AMO aims to become the leader of biomedical imaging. With the passion to solve the unmet medical needs, we are dedicated to bringing the breakthrough development of non-invasive visualization technology to improve healthcare and human welfare.

Our first goal is to focus on the clinical development for dermatology, providing clinicians a more efficient tool in skin diagnosis and skin monitoring. We are also working on the integration of OCT system and artificial intelligence. In the future, we plan to extend our OCT application in ophthalmology, pathology, endoscopy, and basic research markets. AMO will continue to advance our technology to provide the best imaging system.

AMO’s Key Milestones

  • Technology transfer from National Taiwan University


  • Apollo Medical Optics, Ltd. was formally established in Taipei, Taiwan

  • Awarded Incubation project grant by Ministry of Economic Affairs


  • Awarded Subsidies & Incentives for Taipei Industry by Taipei City Government


  • Obtained ISO 13485:2016 certification


  • ApolloVue® B100 Image System received Taiwan GMP certificate



  • Awarded Cross Industry Biomedical Integration Program Grant by Ministry of Science and Technology

  • Awarded A+ Industrial innovative R&D Grant by Ministry of Economic Affairs

  • Received approval of factory registration

  • Received medical device manufacturing license


  • ApolloVue® S100 Image System received Taiwan GMP certificate

  • ApolloVue® S100 Image System received US 510K clearance

  • ApolloVue® S100 Image System awarded the Taiwan Excellence Award

  • ApolloVue® S100 Image System awarded the 17th Taiwan Innovation Award



  • ApolloVue® S100 Image System received Taiwan FDA approval


  • AppWorks has taken the lead in wrapping up AMO's third round of funding, combining investments from the original investors and the AMO team.

  • AMO has started developing a handheld, portable, and high-resolution FF-OCT device.

  • At the 2022 EADV conference, AMO's skin cancer research results debuted with a poster presentation featuring groundbreaking findings from a top-notch dermatology imaging expert in Europe.


Need help?

Save time by starting your support request online and we'll connect you to an expert.